Lonza Group AG

Lonza Completes Acquisition of Large-Scale Biologics Site in Vacaville (US) from Roche

Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)

Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds

Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members

Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand

Q1 2024 Qualitative Update: Performance In Line with Expectations for Full-Year 2024

Lonza Announces Results of the 2024 Annual General Meeting – All Motions Proposed by Board of Directors Approved

Lonza Prices EUR 1 Billion Straight Bond with a 3.875% Coupon

Lonza Publishes Invitation to the 2024 Annual General Meeting and 2023 Annual and Sustainability Reports

Lonza Appoints Wolfgang Wienand as New Chief Executive Officer

Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche

Jean-Marc Huët to succeed Albert M. Baehny as Chairman of Lonza

Lonza Delivers Solid 2023 Performance with 10.9% CER Sales Growth and 29.8% CORE EBITDA Margin

Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds

Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects

Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer

Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023

Board Announcement

Lonza Delivers 5.6% CER Sales Growth, With Underlying Growth at Around 10% CER and 30% CORE EBITDA Margin

Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering

Q1 2023 Qualitative Update: Business Performance In Line With  Full-Year Trajectory

Lonza Announces Results of the 2023 Annual General Meeting – All Motions Proposed by Board of Directors Accepted

Lonza Increases Straight Bond by CHF 150 Million

Lonza Launches Share Buyback Program of up to CHF 2 Billion

Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)

Lonza Publishes Invitation to the 2023 Annual General Meeting and 2022 Annual and Sustainability Reports

Lonza Completes Expansion of Conjugation Facility in Visp (CH)

​​Lonza Prices CHF 300 Million Straight Bond with a 2.100% Coupon​

Lonza Delivers Strong 2022 Performance with 15.1% CER Sales Growth and 32.1% CORE EBITDA Margin